Clinical Trials | January 24, 2022
RaphaCure partners with Madhavbaug for cardiac healthcare services
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
They will commercialize molnupiravir in the international markets
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Subscribe To Our Newsletter & Stay Updated
